

A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)

Children's Hospital Oakland, Oakland, California, United States

Children's Hospital of Orange County, Orange, California, United States

University of Minnesota, Minneapolis, Minnesota, United States

Baylor College of Medicine, Houston, Texas, United States

Hospital Infantil Candido Fontoura Sao Paulo, Sao Paulo, , Brazil

Centenario Hospital Miguel Hidalgo, Pediatrics, Aguascalientes, , Mexico

Unidade de Doenças Metabólicas - Centro Hospitalar do Porto, Porto, , Portugal

The primary objective of the study is to evaluate the long-term safety of UX003 in subjects with MPS 7.